CNBC · 18:53 · 06/29 NEUTRAL BULLISH

Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities

Eli Lilly (LLY) and Regeneron (REGN) have secured early entry into the FDA's PreCheck Pilot Program, a regulatory initiative designed to...

finance.yahoo.com · 07:55 · 06/29 NEUTRAL BULLISH

Eli Lilly and Company (LLY) Up More Than 6% Over the Past Month, Can it Move Higher?

Eli Lilly (LLY) has demonstrated positive momentum with a 6% monthly gain, supported by analyst upgrades and consensus price targets...

seekingalpha.com · 16:22 · 06/26 NEUTRAL BULLISH

Lilly, J&J, AbbVie hit all-time highs (LLY:NYSE)

Three large-cap Health Care names—Eli Lilly (LLY), Johnson & Johnson (JNJ), and AbbVie (ABBV)—have reached new 52-week highs, signaling...

CNBC · 14:08 · 06/26 NEUTRAL BEARISH

Why breakthrough GLP-1 weight loss pills may be a bad thing for employer insurance coverage

The rapid adoption of GLP-1 weight-loss medications from Novo Nordisk and Eli Lilly presents a fundamental coverage disconnect between...

CNBC · 18:52 · 06/25 HIGH BULLISH

Obesity drugs approach a major milestone, and Lilly may have a 'game changer' ahead

Eli Lilly (LLY) appears positioned for a significant catalyst event tied to obesity drug advancement. The reference to an imminent "game...

thehindubusinessline.com · 15:23 · 06/25 NEUTRAL BULLISH

Lilly launches cancer therapy drug Tanstrive

Eli Lilly (LLY) has launched Tanstrive, a targeted oral cancer therapy designed for RET-altered tumors, marking another expansion in its...

livemint.com · 12:44 · 06/25 NEUTRAL BULLISH

Tanstrive cost, dosage: Eli Lilly launches cancer drug in India, priced at ₹2.15 lakh per box

Eli Lilly has expanded its oncology portfolio into the Indian market through the launch of Tanstrive, a cancer therapeutic priced at...

insidermonkey.com · 04:16 · 06/25 NEUTRAL BULLISH

Eli Lilly and Company (LLY) – Among the 10 Reliable Dividend Stocks to Buy for Long-Term Investors

Eli Lilly (LLY) has signaled a material expansion of its weight-loss pharmaceutical portfolio into European markets, with European Union...

seekingalpha.com · 19:51 · 06/24 NEUTRAL BULLISH

Absci: Eli Lilly Backs Alopecia Data With Funding, But Risks Remain (NASDAQ:ABSI)

ABSI rallied 30% on the back of a $100M equity investment from pharmaceutical heavyweight Eli Lilly, signaling institutional validation...

manilatimes.net · 01:24 · 06/24 NEUTRAL BULLISH

Abbisko Therapeutics Deepens R&D Collaboration with Lilly

Eli Lilly and Company (LLY) has formalized a strategic research collaboration with Abbisko Therapeutics, a Hong Kong-listed biotech...

finance.yahoo.com · 14:34 · 06/23 NEUTRAL BULLISH

Eli Lilly vs Viking Therapeutics: Which GLP-1 Stock Is the Better Buy?

The GLP-1 pharmaceutical market continues to demonstrate robust secular growth tailwinds, with both Eli Lilly (LLY) and Viking...

manilatimes.net · 12:30 · 06/23 HIGH BEARISH

Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas

Sangamo Therapeutics (SGMO) has entered into asset sale agreements with Eli Lilly (LLY) and Astellas Pharma as part of a voluntary...

manilatimes.net · 20:18 · 06/22 HIGH BULLISH

Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales

Eli Lilly's (LLY) acquisition of Centessa Pharmaceuticals (CNTA) has cleared a major regulatory hurdle with High Court approval in...

GlobalNewswire · 20:05 · 06/22 HIGH BULLISH

Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales

Eli Lilly's acquisition of Centessa Pharmaceuticals has received final regulatory clearance from the UK High Court, removing the last...

finance.yahoo.com · 13:10 · 06/22 NEUTRAL BULLISH

Is Eli Lilly and Company (LLY) among the Best Longevity and Anti-Aging Stocks to Buy?

Eli Lilly (LLY) has been identified among a curated list of longevity and anti-aging stocks, reflecting sustained institutional interest...

seekingalpha.com · 13:05 · 06/21 NEUTRAL NEUTRAL

Notable healthcare headlines for the week: Merck, Moderna, and Biogen in focus

Healthcare equities displayed mixed performance amid divergent fundamental catalysts. Moderna (MRNA) outperformed the XLV health care...

finance.yahoo.com · 21:35 · 06/20 NEUTRAL NEUTRAL

Pfizer's Dividend Yield is 10X Bigger Than Eli Lilly's. Does That Make It the Better Stock for Income Investors?

This analysis compares Pfizer (PFE) and Eli Lilly (LLY) through the lens of dividend yield differentials, highlighting a significant...

investing.com · 15:41 · 06/18 NEUTRAL BULLISH

3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound

Eli Lilly (LLY), Humana (HUM), and DexCom (DXCM) are emerging as primary drivers of healthcare sector strength, signaling renewed...

finance.yahoo.com · 16:38 · 06/17 NEUTRAL BULLISH

Jim Cramer on Eli Lilly: “I Want You to Stay in the Stock”

Eli Lilly (LLY) received a bullish endorsement from Jim Cramer on Mad Money, reinforcing positive sentiment around the pharmaceutical...

cnbc.com · 19:09 · 06/16 NEUTRAL BULLISH

Lilly opens its checkbook again, and an insider buy at Broadcom captures our attention

Eli Lilly (LLY) has signaled continued capital deployment appetite through major acquisition or investment activity, reinforcing...

manilatimes.net · 17:05 · 06/16 NEUTRAL BULLISH

Glioblastoma Clinical Trial Landscape Expands: Over 200 Companies Advancing Next-Generation Therapies | DelveInsight

The glioblastoma therapeutic pipeline is experiencing significant expansion with over 220 companies advancing clinical-stage candidates,...

SeekingAlpha · 14:14 · 06/16 NEUTRAL BULLISH

Lilly acquires pain therapy developer 4E Therapeutics

Eli Lilly (LLY) has acquired 4E Therapeutics, a developer focused on pain management therapies. This strategic move expands Lilly's...

livemint.com · 08:09 · 06/16 NEUTRAL BULLISH

Biocon eyes crown of world’s top insulin supplier amid rush for GLP-1

Biocon's strategic pivot toward insulin market leadership represents a significant capital allocation decision within the global...

economictimes.indiatimes.com · 07:39 · 06/16 NEUTRAL BULLISH

Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for Biocon

Biocon's strategic pivot to dominate global insulin supply within five years signals a structural shift in pharmaceutical competitive...

insidermonkey.com · 08:50 · 06/13 NEUTRAL BULLISH

10 Most Profitable Blue Chip Stocks to Buy According to Hedge Funds

This listicle aggregates hedge fund positioning on large-cap profitable companies, with LLY and JPM as detected holdings. The timing...

rttnews.com · 15:36 · 06/12 HIGH BULLISH

Weekly Buzz: GH, LLY Gain FDA Nod; TEVA, GSK, Lead M&A Wave; ZEAL, LLY Post Strong Data

Eli Lilly (LLY) and peer biotech firms secured FDA approvals across oncology, dermatology, and rare disease indications this week,...

ventureburn.com · 16:00 · 06/11 LOW NEUTRAL

SonoThera Raises $125M to Advance Gene Therapy

SonoThera's $125M Series B funding round represents incremental capital deployment in the competitive nonviral gene therapy space. While...